If you have been reading about forced degradation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Acylated GLP-1 receptor agonist | 31-residue synthetic peptide |
| Molecular formula | C187H291N45O59 | established for the free peptide |
| Appearance | White to off-white powder | as supplied before formulation |
| Solubility | Freely soluble in water | aqueous buffers near neutral pH |
| Typical storage | 2 to 8 degrees Celsius, protected from light | powder and solution forms differ in shelf life |
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Stability studies focus on deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation into higher-order species. The fatty acid side chain adds susceptibility to oxidative change and can promote self-association at high concentration. Lyophilised material is comparatively robust when kept cold and dry, while aqueous solutions require refrigeration and protection from light. Forced degradation experiments under heat, acid, base, and peroxide conditions establish the specificity of each analytical method. Which degradation route dominates under real storage conditions depends on the formulation and stays formulation-specific.
Handling guidance for research quantities calls for single-use aliquots, an inert atmosphere where practical, and avoidance of repeated freeze-thaw cycles that accelerate aggregation. Certificates of analysis typically report purity by peak area, water content, counter-ion identity, and residual solvent levels. In the scientific literature the compound is usually described by its full amino acid sequence, its registry number, or its structural class rather than by any proprietary label. Reporting standards vary between journals, and reviewers increasingly request raw chromatograms alongside tabulated purity figures. Whether current purity thresholds are adequate for every experimental context is debated.
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the dominant approach for peptide purity assessment, usually paired with mass spectrometry to confirm molecular mass and sequence. Peptide mapping by enzymatic digestion and tandem mass spectrometry locates modifications such as deamidation and oxidation. Quantitation in plasma matrices can be performed by LC-MS/MS after solid-phase extraction. Method validation follows general guidance on accuracy, precision, linearity, and limits of detection. Comparability of results between laboratories, when no shared reference standard is available, remains an open question.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
== Use == So far, biomass-based production of industrial microalgae has been widely applied in the fields from food and feed to high-value chemicals for pharmaceutical and ecological applications. Although the commercial cultivation of microalgae became increasingly popular, only algal biomass is processed to current products, while huge volumes of algae-free media are unexploited in flow through cultures and after biomass harvesting of batch cultures. Medium recycling to save culturing costs faces the big risk of growth inhibition. High volumes of spent media give rise to environmental pollution and cost of water and nutrition supply in cultivation when the media are discarded directly to the environment. Therefore the application of recycling methods motivated by the simultaneous generation of high value products from spent medium bears potential in commercial and environmental perspectives.
==== Second order kinetics ==== In second order reactions, the rate of reaction is proportional to the square of the concentration. By integrating this rate, it can be shown that the concentration [A] of the reactant decreases following this formula:
==== Tangier disease ==== Tangier disease is also linked to CL abnormalities. Tangier disease is characterized by very low blood plasma levels of HDL cholesterol, accumulation of cholesteryl esters in tissues, and an increased risk for developing cardiovascular disease. Unlike Barth syndrome, Tangier disease is mainly caused by abnormal enhanced production of CL. Studies show that there are three to fivefold increase of CL level in Tangier disease. Because increased CL levels would enhance cholesterol oxidation, and then the formation of oxysterols would consequently increase cholesterol efflux. This process could function as an escape mechanism to remove excess cholesterol from the cell.
=== Lysine price fixing === In 1986, the Ajinomoto Group produced lysine at its Iowa factory of Heartland Lysine Co. U.S.A., followed by production in its Pathum Thani factory in Ajinomoto, Thailand, in 1986, and Bio Italia, BioPro in Italy in 1992, gradually upgrading its worldwide production bases. In the United States, competitors increased their own lysine production, which resulted in lower prices due to an overabundance of lysine on the market. To raise prices again, several companies, including Ajinomoto, price fixed lysine in the 1990s. Along with Kyowa Hakko Kogyo and Sewon America, Inc., Ajinomoto admitted to price fixing and settled with the United States Department of Justice Antitrust Division in September 1996. Each firm and an executive from each pleaded guilty as part of a plea bargain to aid in further investigation. Their cooperation led to Archer Daniels Midland settling charges with the US government in October 1996 for $100 million, a record antitrust fine at the time. Cartels were able to raise lysine prices 70% within the first six months of cooperating.
Sources: en.wikipedia.org
== External links == Interview with Roderick MacKinnon by Harry Kroto Freeview video provided by the Vega Science Trust. Website of his lab at The Rockefeller University Ion Channel Chemistry: The Electrical System of Life Transcribed video of a May 2008 talk by MacKinnon, sponsored by the Oregon State University Libraries. Nobel Lecture by Roderick MacKinnon, 2003 Introduction to Neuroscience by Donald C.Cooper Roderick MacKinnon on Nobelprize.org
Szára, who later worked for the United States National Institutes of Health, researched DMT after his order to acquire LSD from the Swiss company Sandoz Laboratories was rejected on the grounds that the powerful psychotropic could be dangerous in the hands of a communist country. In his paper Dimethyltryptamin: Its Metabolism in Man; the Relation of its Psychotic Effect to the Serotonin Metabolism, Szara employed synthetic DMT, synthesized by the Speeter–Anthony route, which was then administered to 20 volunteers by intramuscular injection. Urine samples were collected from these volunteers for the identification of DMT metabolites. This is considered to be the link between the chemical structure of DMT and its cultural consumption as a psychoactive and religious sacrament. Another historical milestone was the discovery of DMT in plants frequently used by Amazonian natives as additive to the vine Banisteriopsis caapi to make ayahuasca decoctions. In 1957, American chemists Francis Hochstein and Anita Paradies identified DMT in an "aqueous extract" of leaves of a plant they named Prestonia amazonicum [sic] and described as "commonly mixed" with B. caapi. The lack of a proper botanical identification of Prestonia amazonica in this study led American ethnobotanist Richard Evans Schultes (1915–2001) and other scientists to raise serious doubts about the claimed plant identity. The mistake likely led the writer William Burroughs to regard the DMT he experimented with in Tangier in 1961 as "Prestonia".
Narrated by Paul Brightwell, produced by David Sington, directed by David McNab, made by Dox Productions 4 March The Engines That Came in from the Cold, about the Russian N1 rocket with an unexpected and surprising outcome to the documentary, and a reference to the 1963 book The Spy Who Came in from the Cold; George Mueller, head of Apollo programme from 1963 to 1969; Charles Vick of the Federation of American Scientists; Sergei Korolev, chief designer at OKB-1; Vasily Mishin, deputy chief designer at OKB-1, had done calculations showing that to get a cosmonaut on the Moon, it required a 100 tonne vehicle in orbit, which would require a 2,000 tonne vehicle at lift-off; Valentin Anisimov, chief designer at Kuznetsov Design Bureau, and how Korolev approached the Kuznetsov company, to make the new rocket engines for the proposed N1 rocket launcher, but it was too new and large to develop from scratch, so thirty pre-existing engines would be deployed, and the pre-burner which powered the rocket pumps would become a closed cycle, to improve power by 25%, but this was vastly untested; the first twelve launches would be uncrewed, followed by two test crewed launches, and the Soviet limited budget meant that development was not at a sufficient stage (that NASA would have arrived at) before the launches were carried out; this first uncrewed launch took place on 21 February 1969, and one minute into the flight, the rocket exploded; the N1 had a thrust of 4,500 tonnes at launch; the N1 second launch took place on 3 July 1969, after the engine control system was modified, and a few seconds after launch the engine cut out, and the whole N1 launcher fell onto the launch pad, causing total catastrophic results - this explosion stopped any further Soviet Union attempt to reach the Moon with a crewed rocket, the launch pad damage was unrecoverable; two weeks later Apollo 11 landed on the Moon; the N1 next launch was on 26 June 1971, with a rebuilt launch pad, and this launch exploded one minute into the flight; the fourth launch of the N1 on 23 November 1972 exploded two minutes into the flight; by the mid-1970s the Kuznetsov NK-33 closed-cycle engine, for the N1, had been sufficiently tested in its development lifetime; the Soviet Moon mission was around four years behind NASA, and when the engines were finally sufficiently tested, the whole Soviet Moon programme was stopped in 1974; any N1 engines and systems were instructed to be removed, to eliminate its knowledge; only in the early 1990s did knowledge of the N1 first appear; Bob Ford of Lockheed Martin and Bill Hoffman of Aerojet; Kuznetsov had nonetheless kept around sixty NK-33 engines in Samara - the home of Soviet rocketry, and wanted to show these engines to visitors from Aerojet; after a successful test of an NK-33 at Sacramento in October 1995, the NK-33 was developed into the RD-180, which powered the American Lockheed Martin Atlas III rocket; John Karas, of Lockheed Martin, at the first launch of an American rocket, on 24 May 2000 of the Eutelsat 36A satellite, that was powered by a Russian engine - the RD-180, which was twice as powerful as the NK-33, and one engine could replace five engines of the previous Atlas II; Vladimir Chvanov and Boris Katorgin, designers at NPO Energomash; the American rocket engineers had viewed the closed-cycle method as far too dangerous, and it was dangerous, but Russian engineers had developed new stainless steel alloys to largely overcome this danger. Narrated by Jaye Griffiths, produced by Hamish Barbour, directed by, made by Ideal World Productions 17 June The Day the Oceans Boiled, about the Earth's environment; 55 million years ago, the Earth was 6C hotter than it is now, with no ice caps, and trees grew at Antarctica, the temperature became 8C hotter, known as the Paleocene-Eocene Thermal Maximum; mammals shrunk in how large; since 55m years ago, carbon dioxide has been absorbed by plants, cooling the Earth; climate models were derived from weather forecast models; Peter Cox (climatologist) of the Met Office, and carbon sinks, and how each year 6 billion tonnes of carbon dioxide enters the atmosphere, but the effect appears to be only from around 3 billion tonnes; Antonio Nobre of the National Institute of Amazonian Research - he found that the Amazon forest, and its 500 million hectares of trees, was a much bigger carbon sink than presumed - it could be absorbing three-quarters of the carbon dioxide of all the world's vehicles; the Greenland Ice Sheet Project, and Geoffrey Hargreaves at the National Science Foundation Ice Core Facility (NICL) in Colorado, and ice cores from the Vostok Station; the Earth has warmed and cooled in a 100,000 years cycle; the Met Office model predicted that after 2050, due to shortage of rainfall seasons, the Amazon forest would not act as a carbon sink; Carlos Nobre (scientist) and dry seasons, and the possible danger of fire, caused by changes in the tropical climate; Richard Corfield (scientist); Philip D. Gingerich of the University of Michigan; Santo Bains was researching the Paleocene-Eocene boundary, so went to the Gulf Coast Repository, and looked at Core 690 drilled by JOIDES Resolution of the Ocean Drilling Program from the Weddell Sea, and concluded that rapid changes in Earth temperature came from methane clathrates (methane hydrates); geologist Euan Nisbet; the Earth returned to lower temperatures after 60,000 years. Narrated by Matthew Zajac, directed by David Sington, made by Dox Productions 24 June The Fish That Time Forgot, about the coelacanth; Margery Courtney Latimer in 1938 of the Natural History Museum, London, and a fish caught at East London; J. L. B. Smith, from Grahamstown, of Rhodes University; the American Museum of Natural History; evolutionary biologist John McCusker; the Comoro Islands, run by the French, near Madagascar, where another fish was found in 1952; Mike Ruton; Robin Stobbs; the JAGO (German research submersible) and Hans Fricke of the Max Planck Institute for Behavioral Physiology, who found a live fish on 17 January 1987; Susan Jewett of the National Museum of Natural History in Washington; on 30 July 1998, a live female fish is found on a beach in Indonesia by Mark Erdmann. Narrated by Robert Lindsay, produced by Ron Ackerman, directed by Celia Lowenstein, made by Diverse Productions with Nova 8 July The Secret Life of the Mouse, about the laboratory mouse; zoologist Sam Berry of UCL; mouse geneticist Jo Peters of MRC Harwell; Irving Weissman; most genetic research is done with mice, with 25 million a year; Steve Brown, Director of MRC Harwell; the mouse has 99.9% of the genes of humans; the Jackson Laboratory has 1m mice and around 1,000 human staff, with 2,500 strains of mice, who have mouse models of human diseases, and mice breed much quicker than humans do; Beverly Paigen; in one year, there are three generations of mice; twenty Nobel prizes have depended on mouse research; Cliffe Rosen of the Maine Center of Osteoporosis Research; scientists want mutant mice for each gene; Charles Vacanti of the University of Massachusetts Medical School, whose cartilage research led to a mouse having an artificial cartilage human ear grown on its back; Philip Leder of Harvard Medical School, who placed a patent on a mouse; a fluorescent mouse; Hank Greely of Stanford University; it ends with the opening lines from A Tale of Two Cities. Narrated by Stephen Fry, produced by David Paterson, directed by Kevin Hull, made by BOA 2001. The documentary has overtones of the music video of the 2001 Where's Your Head At, made in the same year as the documentary 15 July Saving the Leaning Tower, a documentary chronicling the dramatic rescue of one of the world’s most iconic landmarks. By the late 1980s, the Leaning Tower of Pisa was on the brink of collapse, its southward tilt increasing steadily and threatening catastrophic failure. Alarm spread after the sudden fall of a medieval bell tower in Pavia in 1989, which convinced authorities to close Pisa’s monument to the public. An international committee of engineers, geologists, and historians was formed to save the tower, among them British civil engineer John Burland. Through detailed investigation, the team uncovered the structural weaknesses behind the marble façade and the unstable soils beneath Pisa. Computer models showed the tower should already have collapsed. Temporary steel tendons and 600 tonnes of lead counterweights prevented immediate disaster, but the tower’s fate remained uncertain. Burland proposed a novel, delicate solution: controlled “soil extraction” below the northern side to allow the tower to gently tilt back to stability. The project was plagued by risks, political disputes, and near-disasters, including the “Black September” of 1995, when freezing the foundations caused the tower to lurch alarmingly. Despite opposition, the soil extraction method was eventually approved in 1998. Over two years, engineers removed around 70 tonnes of soil, gradually reducing the lean by half a meter without visible alteration to the monument. By June 2001, the tower had been successfully stabilized, restored to the inclination it had in the 18th century, and reopened to the public. The operation was hailed as one of the greatest feats of modern civil engineering, ensuring the survival of Pisa’s unique heritage for centuries to come. The documentary presents not only the technical challenges but also the cultural, historical, and emotional significance of preserving this medieval masterpiece. 13 October Battle of the Robots: The Hunt for AI, about the work of Hugo de Garis, Rodney Brooks, and Steve Grand (roboticist); the documentary opens with the archetypal and iconic robot HAL 9000 from the 1968 2001: A Space Odyssey (film) and The Blue Danube; Igor Aleksander, who worked in neural systems at Imperial College London, and his views on the likelihood of computational intelligence; Dan Dennett; British roboticist Steve Grand, of North Somerset made the world's first AI computer game Creatures in 1996, and was designing a glider that could teach itself; Blay Whitby of the University of Sussex; the MIT Computer Science and Artificial Intelligence Laboratory and Brian Scassellati, who was designing a social robot called Cog (project); Belgian Walter De Brouwer of Starlab in Belgium; engineer Kevin Warwick of the University of Reading at the 2001 Royal Society Prizes for Science Books (Aventis Prize for Science Books), won by Robert Kunzig. Narrated by Patrick Forbes, produced by Nicolas Kent 28 October Bioterror, an Equinox Special, about biological weapons, with Judith Miller and her 2001 book Germs: Biological Weapons and America's Secret War; Robert Kadlec of the National War College; science writer William Broad; the ATCC in Manassas, Virginia; microbiologist William C. Patrick III; the 2001 anthrax attacks; microbiologist Richard O. Spertzel; geneticist Matthew Meselson; Gennady Lepyoshkin, Director from 1987 to 2001 of a Russian secret biological research site; Jonathan B. Tucker; Chris Shays; Andrew C. Weber; Sergei Popov (bioweaponeer) had worked at the State Research Center for Applied Microbiology in Obolensk, Moscow Oblast. Produced by Matthew Collins, directed by Kirk Wolfinger, made by WGBH. Shown on Tuesday 20 November 2001 on The Nature of Things in Canada, and on Nova, and on Nova on Tuesday 13 November 2001
Sources: en.wikipedia.org
=== Eye drops vs. other treatments === The TAGS randomised controlled trial investigated whether eye drops or trabeculectomy is more effective in treating advanced primary open-angle glaucoma. After two years, researchers found that vision and quality of life are similar in both treatments. At the same time, eye pressure was lower in people who underwent surgery, and in the long run, surgery is more cost-effective. The LiGHT trial compared the effectiveness of eye drops and selective laser trabeculoplasty for open-angle glaucoma. Both contributed to a similar quality of life, but most people undergoing laser treatment were able to stop using eye drops. Laser trabeculoplasty was also shown to be more cost-effective.
==== Spinal ==== Spinal fusion can be performed either as a preventative measure or to correct existing scoliosis, although the inherent fragility of OI bone makes this operation more complex in OI patients than it does with patients who have adolescent idiopathic scoliosis, but normal bone density. Despite the risks, however, three Nemours–duPont orthopedic surgeons who specialize in surgical intervention for osteogenesis imperfecta recommend operating if the curve is greater than 50° after a child is past peak height velocity, as the spine's curve can continue to worsen even into adulthood. Due to the risk involved, the same surgeons recommend that surgery for basilar impressions and basilar invaginations should only be carried out if the pressure being exerted on the spinal cord and brain stem is causing actual neurological symptoms. Once basilar invagination has become symptomatic, only surgery can halt or reverse the progression of neurological deficits.
== Production and function == Hydroxyproline is produced by hydroxylation of the amino acid proline by the enzyme prolyl 4-hydroxylase following protein synthesis (as a post-translational modification). The enzyme-catalyzed reaction takes place in the lumen of the endoplasmic reticulum. Although it is not directly incorporated into proteins, hydroxyproline comprises roughly 4% of all amino acids found in animal tissue, an amount greater than seven other amino acids that are translationally incorporated.
Six isotopes of flerovium are known, ranging in mass number between 284 and 289; the most stable of these, 289Fl, has a half-life of ~2.1 seconds, but the unconfirmed 290Fl may have a longer half-life of 19 seconds, which would be one of the longest half-lives of any nuclide in these farthest reaches of the periodic table. Flerovium is predicted to be near the centre of the theorized island of stability, and it is expected that heavier flerovium isotopes, especially the possibly magic 298Fl, may have even longer half-lives.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.
The fatty diacid chain associates strongly with serum albumin, which keeps the peptide in circulation and shields it from rapid renal clearance. Bound peptide is released gradually, producing a sustained receptor signal. This mechanism also reduces the peak-to-trough variation seen with shorter-acting analogues.
The balance between peripheral receptor activation and signalling in the central nervous system is not fully resolved. The extent to which slowed gastric emptying accounts for reduced energy intake, compared with direct effects on appetite circuits, is debated. Long-term effects on lean mass and on tissues outside the gut and brain are still under study.
It is a synthetic analog of GLP-1 produced through medicinal chemistry to resist enzymatic degradation. The design goal was longer circulation than the native hormone.